Benzphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol. The serum concentration of Paritaprevir can be increased when it is combined with Fusidic Acid. The risk or severity of adverse effects can be increased when Midazolam is combined with Meclizine. Tolazoline may increase the hypotensive activities of Manidipine. Fenofibric acid may increase the hypoglycemic activities of Glimepiride. The metabolism of Cyclosporine can be decreased when combined with Nystatin. The risk or severity of adverse effects can be increased when Rescinnamine is combined with Parthenolide. Tolmetin may decrease the antihypertensive activities of Oxprenolol. The serum concentration of Neomycin can be decreased when it is combined with Phenoxymethylpenicillin. The risk or severity of adverse effects can be increased when Procarbazine is combined with Salmeterol. Lisinopril may increase the hypotensive activities of Rescinnamine. Caroxazone may increase the hypotensive activities of Cyclopenthiazide. The risk or severity of adverse effects can be increased when Fenoprofen is combined with Nimesulide. The risk or severity of adverse effects can be increased when Sevoflurane is combined with Perindopril. The risk or severity of adverse effects can be increased when Reserpine is combined with Minoxidil. The risk or severity of adverse effects can be increased when Hexobarbital is combined with Zonisamide. The risk or severity of adverse effects can be increased when E-6201 is combined with Flumethasone. The metabolism of Betaxolol can be decreased when combined with Haloperidol. The risk or severity of adverse effects can be increased when Candesartan is combined with Zofenopril. The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Brompheniramine. The metabolism of Valbenazine can be decreased when combined with Clotrimazole. Ethylmorphine may increase the serotonergic activities of Milnacipran. The metabolism of Miconazole can be decreased when combined with Dronedarone. The serum concentration of Fluocinonide can be decreased when it is combined with Phenobarbital. The metabolism of Ethinyl Estradiol can be decreased when combined with Telithromycin. The metabolism of Etravirine can be increased when combined with Secobarbital. Guanadrel may increase the hypotensive activities of Candesartan. The serum concentration of Conivaptan can be increased when it is combined with Atazanavir. The serum concentration of Cyclobenzaprine can be increased when it is combined with Sitagliptin. The serum concentration of Polythiazide can be increased when it is combined with Tiotropium. Indapamide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level. The metabolism of Methylphenobarbital can be decreased when combined with Abiraterone. Indomethacin may decrease the antihypertensive activities of Bufuralol. The metabolism of Fosphenytoin can be decreased when combined with Pyrimethamine. Levodopa may increase the sedative activities of Metyrosine. Brimonidine may increase the hypotensive activities of Rituximab. Ritonavir may increase the QTc-prolonging activities of Gemifloxacin. Pentoxifylline may increase the hypotensive activities of Amlodipine. Harmaline may increase the hypotensive activities of Penbutolol. The serum concentration of Cyclopenthiazide can be increased when it is combined with Solifenacin. The risk or severity of adverse effects can be increased when Lisuride is combined with Iloperidone. Trichlormethiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level. Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ofloxacin. The risk or severity of adverse effects can be increased when Imipramine is combined with Telmisartan. Hydroxyamphetamine may decrease the sedative activities of Buclizine. The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Pilocarpine resulting in a loss in efficacy. The metabolism of Famotidine can be decreased when combined with Cholecalciferol. The serum concentration of Abacavir can be decreased when it is combined with Remikiren. The metabolism of Buprenorphine can be decreased when combined with Cimetidine. The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salsalate. The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alaproclate. The metabolism of Hexobarbital can be decreased when combined with Imatinib. Guanabenz may increase the hypotensive activities of Metipranolol. The serum concentration of Sulfadiazine can be increased when it is combined with Simeprevir. The metabolism of Clofibrate can be decreased when combined with Ketoconazole. The serum concentration of Atorvastatin can be increased when it is combined with Daclatasvir. Prazosin may decrease the vasoconstricting activities of Ergotamine. The risk or severity of adverse effects can be increased when Flucytosine is combined with Lercanidipine. The metabolism of Letermovir can be decreased when combined with Clemastine. The metabolism of Artemether can be decreased when combined with Clotrimazole. The therapeutic efficacy of Ancrod can be decreased when used in combination with Dienogest. Sufentanil may increase the orthostatic hypotensive activities of Levodopa. The metabolism of Nortriptyline can be decreased when combined with Bupropion. The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertraline. The risk or severity of adverse effects can be increased when Morphine is combined with Methohexital. The risk or severity of adverse effects can be increased when Tamsulosin is combined with Quetiapine. The metabolism of Glyburide can be decreased when combined with Manidipine. Anisotropine Methylbromide may increase the anticholinergic activities of Glycopyrronium. The risk or severity of adverse effects can be increased when Nimesulide is combined with Aminosalicylic Acid. Ergotamine may increase the hypertensive activities of Synephrine. Adapalene may increase the neuroexcitatory activities of Nalidixic Acid. Udenafil may increase the antihypertensive activities of Polythiazide. The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Darunavir. Eplerenone may increase the hyperkalemic activities of Rescinnamine. The metabolism of Zalcitabine can be decreased when combined with Cimetidine. The serum concentration of Dihydroergotamine can be increased when it is combined with Cilazapril. Olmesartan may increase the hypotensive activities of Manidipine. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Manidipine. The serum concentration of Pitavastatin can be increased when it is combined with Cobicistat. Etofenamate may decrease the antihypertensive activities of Nadolol. Aliskiren may increase the hyperkalemic activities of Losartan. The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prasterone. The serum concentration of Digoxin can be increased when it is combined with Lisinopril. Minocycline may increase the central nervous system depressant (CNS depressant) activities of Desflurane. The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Dyphylline. The risk or severity of adverse effects can be increased when Budesonide is combined with Memantine. The risk or severity of adverse effects can be increased when Difluocortolone is combined with Grepafloxacin. Imipramine may decrease the antihypertensive activities of Clonidine. The metabolism of Arachidonic Acid can be decreased when combined with Sulfisoxazole. The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Metyrapone resulting in a loss in efficacy. The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Tacrolimus. The risk or severity of adverse effects can be increased when Reserpine is combined with Nicardipine. The metabolism of Fenofibrate can be decreased when combined with Isradipine. The risk or severity of adverse effects can be increased when Nitroprusside is combined with Bumetanide. The metabolism of Tiotropium can be decreased when combined with Atazanavir. The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Bucillamine. The risk or severity of adverse effects can be increased when Semapimod is combined with Carbaspirin calcium. Acetyldigitoxin may decrease the cardiotoxic activities of Dexamethasone. Desvenlafaxine may increase the tachycardic activities of Hexoprenaline. Solifenacin may increase the QTc-prolonging activities of Toremifene. The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Diazoxide. Piroxicam may decrease the antihypertensive activities of Metipranolol. Trandolapril may increase the hypotensive activities of Talinolol. The therapeutic efficacy of Methallenestril can be decreased when used in combination with St. John's Wort. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil. The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Andrographolide. The risk or severity of adverse effects can be increased when Lisuride is combined with Nitric Oxide. Salicylic acid may decrease the antihypertensive activities of Perindopril. The serum concentration of Oxycodone can be increased when it is combined with Fusidic Acid. The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desonide. The serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Atazanavir. Bendroflumethiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level. The therapeutic efficacy of Gemeprost can be decreased when used in combination with Ketorolac. The metabolism of Amitriptyline can be increased when combined with Hexobarbital. Deslanoside may decrease the cardiotoxic activities of Gatifloxacin. The serum concentration of Everolimus can be increased when it is combined with Rifampicin. The metabolism of Piroxicam can be decreased when combined with Floxuridine. Ouabain may decrease the cardiotoxic activities of Hydroxyprogesterone caproate. The metabolism of Nicotine can be decreased when combined with Trimethoprim. The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Semapimod. Triflusal may increase the anticoagulant activities of Rosiglitazone. Oxaprozin may increase the anticoagulant activities of Troxerutin. The metabolism of Palonosetron can be increased when combined with Rifabutin. The risk or severity of adverse effects can be increased when Cordycepin is combined with Nimesulide. Ketanserin may increase the hypotensive activities of Pindolol. The serum concentration of Methallenestril can be decreased when it is combined with Omapatrilat. Metipranolol may increase the hypoglycemic activities of Gliquidone. The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nepafenac. Oxprenolol may increase the hypoglycemic activities of Glyburide.